385 related articles for article (PubMed ID: 25878361)
1. RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward J
Clin Cancer Res; 2015 Apr; 21(8):1802-9. PubMed ID: 25878361
[TBL] [Abstract][Full Text] [Related]
2. Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects.
Marcus K; Mattos C
Clin Cancer Res; 2015 Apr; 21(8):1810-8. PubMed ID: 25878362
[TBL] [Abstract][Full Text] [Related]
3. Targeting RAS: The Elusive Prize.
Bates SE
Clin Cancer Res; 2015 Apr; 21(8):1796. PubMed ID: 25878359
[No Abstract] [Full Text] [Related]
4. Recent Advances in Developing K-Ras Plasma Membrane Localization Inhibitors.
Ye N; Xu Q; Li W; Wang P; Zhou J
Curr Top Med Chem; 2019; 19(23):2114-2127. PubMed ID: 31475899
[TBL] [Abstract][Full Text] [Related]
5. Dragging ras back in the ring.
Stephen AG; Esposito D; Bagni RK; McCormick F
Cancer Cell; 2014 Mar; 25(3):272-81. PubMed ID: 24651010
[TBL] [Abstract][Full Text] [Related]
6. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Cox AD; Der CJ; Philips MR
Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
[TBL] [Abstract][Full Text] [Related]
7. Synthetic lethal genetic screens in Ras mutant cancers.
Yu B; Luo J
Enzymes; 2013; 34 Pt. B():201-19. PubMed ID: 25034106
[TBL] [Abstract][Full Text] [Related]
8. KRAS: A Promising Therapeutic Target for Cancer Treatment.
Wu HZ; Xiao JQ; Xiao SS; Cheng Y
Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
[TBL] [Abstract][Full Text] [Related]
9. Synthetic Lethal Vulnerabilities in
Aguirre AJ; Hahn WC
Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
[TBL] [Abstract][Full Text] [Related]
10. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
Barbie DA; Tamayo P; Boehm JS; Kim SY; Moody SE; Dunn IF; Schinzel AC; Sandy P; Meylan E; Scholl C; Fröhling S; Chan EM; Sos ML; Michel K; Mermel C; Silver SJ; Weir BA; Reiling JH; Sheng Q; Gupta PB; Wadlow RC; Le H; Hoersch S; Wittner BS; Ramaswamy S; Livingston DM; Sabatini DM; Meyerson M; Thomas RK; Lander ES; Mesirov JP; Root DE; Gilliland DG; Jacks T; Hahn WC
Nature; 2009 Nov; 462(7269):108-12. PubMed ID: 19847166
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Ras for cancer treatment: the search continues.
Baines AT; Xu D; Der CJ
Future Med Chem; 2011 Oct; 3(14):1787-808. PubMed ID: 22004085
[TBL] [Abstract][Full Text] [Related]
12. Drug Discovery by Targeting Mutant KRAS.
Ye N
Curr Top Med Chem; 2019; 19(23):2079-2080. PubMed ID: 31762422
[No Abstract] [Full Text] [Related]
13. Ras proteins as therapeutic targets.
Chakraborty A; Linnane E; Ross S
Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Dependencies in RAS-Driven Cancers.
Kimmelman AC
Clin Cancer Res; 2015 Apr; 21(8):1828-34. PubMed ID: 25878364
[TBL] [Abstract][Full Text] [Related]
15. Defeat mutant KRAS with synthetic lethality.
Pang X; Liu M
Small GTPases; 2017 Oct; 8(4):212-219. PubMed ID: 27463838
[TBL] [Abstract][Full Text] [Related]
16. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
Lv J; Wang J; Chang S; Liu M; Pang X
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
[TBL] [Abstract][Full Text] [Related]
17. Targeting the RAS oncogene.
Takashima A; Faller DV
Expert Opin Ther Targets; 2013 May; 17(5):507-31. PubMed ID: 23360111
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic strategies to target RAS-mutant cancers.
Ryan MB; Corcoran RB
Nat Rev Clin Oncol; 2018 Nov; 15(11):709-720. PubMed ID: 30275515
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic Approaches to RAS Mutation.
Scott AJ; Lieu CH; Messersmith WA
Cancer J; 2016; 22(3):165-74. PubMed ID: 27341593
[TBL] [Abstract][Full Text] [Related]
20. Improving Prospects for Targeting RAS.
Singh H; Longo DL; Chabner BA
J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
